Permitted daily exposure from preclinical studies of Ginkgo biloba L. dry extract
DOI:
https://doi.org/10.1590/Keywords:
Permitted daily exposure;, Ginkgo biloba L;, Oral pharmaceutical product;, Toxicity;, Preclinical studies;, GenotoxicityAbstract
Resolution 658/2022 of the Brazilian Regulatory Agency requires the determination of the permitted daily exposure (PDE) of pharmaceutical agents. Ginkgo biloba L. is used therapeutically to treat memory deficits and other brain diseases. However, published results indicate that more studies are needed to confirm the safety of Ginkgo biloba. This study aimed to evaluate the dry extract of Ginkgo biloba L. leaves PDE as an ingredient in an oral pharmaceutical product in preclinical studies using mice. Acute oral toxicity and repeated dose experiments were performed based on OECD guidelines, as well as genotoxicity tests. The results indicate that Ginkgo biloba L. has low acute toxicity, no liver toxicity, and does not alter blood glucose levels. No changes in weight gain were observed, but food intake decreased in males during the first week of treatment at the highest dose. Hematological parameters were not altered in males, whereas females presented lower leukocyte and lymphocyte counts and higher neutrophil counts at the highest dose. The lipid profile was not altered in males, whereas total cholesterol was increased in females. The estimated PDE was 0.1 mg/day and, when related to the maximum residual concentration, indicates that the cleaning process used is safe and does not require reassessment.
Downloads
References
Agência Nacional de Vigilância Sanitária (Brasil). Resolução nº. 658, de 30 de março de 2022. Dispõe sobre as Diretrizes Gerais de Boas Práticas de Fabricação de Medicamentos. Diário Oficial da União 31 mar 2022; Seção 1.
Burnett CL. Safety Assessment of Ginkgo biloba - Derived ingredients as used in cosmetics. Cosmetic Ingredient Review, 2018 Washington, DC. Available from: https://www.cir-safety.org/sites/default/files/Ginkgo%20Biloba.pdf
» https://www.cir-safety.org/sites/default/files/Ginkgo%20Biloba.pdf
Betti AH, Stein AC, Dallegrave E, Wouters ATB, Watanabe TTN, Driemeier D, et al. Acute and repeated-doses (28 days) toxicity study of Hypericum polyanthemum Klotzsch ex Reichardt (Guttiferare) in mice. Food Chem Toxicol. 2012;50(7):2349-2355.
Benjamin J, Muir T, Briggs K, Pentland B. A case of cerebral haemorrhage-can Ginkgo biloba be implicated? Postgrad Med J. 2001;77(904):112-3.
Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins CW et al. The complete German Commission E Monographs - Therapeutic guide to herbal medicines. Austin, TX: American Botanical Council; Boston: Integrative Medicine Communication, 1987.
Bonassi S, Prinzi G, Lamonaca P, Russo P, Paximadas I, Rasoni G, et al. Clinical and genomic safety of treatment with Ginkgo biloba L. leaf extract (IDN 5933/Ginkgoselect®Plus) in elderly: a randomised placebo-controlled clinical trial [GiBiEx]. BMC Complement Altern Med. 2018;18(1):22.
Brasil. Lei N° 11974, de 8 de outubro de 2008. Regulamenta o inciso VII do § 1º do art. 225 da Constituição Federal, estabelecendo procedimentos para o uso científico de animais; revoga a Lei nº 6.638, de 8 de maio de 1979; e dá outras providências. Diário Oficial da União 09 outubro 2008; Seção 1.
Bücker A, Carvalho W, Alves-Gomes JA. Avaliação da mutagênese e genotoxicidade em Eigenmannia virescens (Teleostei: Gymnotiformes) expostos ao benzeno. Acta Amaz. 2006;36(3):357-364.
BULARIO.COM. [cited 2023 Jan 16] Available from: https://www.bulario.com/ginkgo >
» https://www.bulario.com/ginkgo
Caria H, Chaveca T, Laires A, Rueff J. Genotoxicity of quercetin in the micronucleus assay in mouse bone marrow erythrocytes, human lymphocytes, V79 cell line and identification of kinetochore-containing (CREST staining) micronuclei in human lymphocytes. Mutat Res. 1995;343(2-3):85-94.
Conselho Nacional de Controle da Experimentação Animal. CONCEA. Normative Resolution No. 37, of February 15, 2018. Guidelines for the Practice of Euthanasia of the National Council for the Control of Animal Experiments - CONCEA. Brasília: Federal Official Gazette No. 36, 2018.
da Silva JCG, Dallegrave E, Rodrigues GZP, Bigolin C, Neumann TMSO, Schuster AC, et al. Repeated dose of meloxicam induces genotoxicity and histopathological changes in cardiac tissue of mice. Drug Chem Toxicol. 2022;45(2):822-833.
Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil. 2000;81(5):668.
European Medicines Agency. EMA. ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. 2009.
European Medicines Agency. EMA. Committee on Herbal Medicinal Products (HMPC). Assessment report on Ginkgo biloba L., folium. 2014
European Medicines Agency. EMA. Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Ginkgo biloba L., folium. 2015
European Medicines Agency. EMA. ICH guideline Q3C (R8) on impurities: guideline for residual solvents. 2022
Fessenden JM, Wittenborn W, Clarke L. Ginkgo biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholescystectomy. Am Surg. 2001;67(1):33-5.
Filho AC, Fakoury MK, Ferry FRA. Ginkgo biloba and memory - systematic review. Rev Bras Geriatr Gerontol. 2010;13(1):145-152.
Garcia EC, Solis IM. Manual de Fitoterapia. Spain, 2nd ed, 1998.
Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo Biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065-2077.
Hauser D, Gayowski T, Singh N. Bleeding complications precipitated by unrecognized Ginkgo biloba use after liver transplantation. Transpl Int. 2002;15(7):377-9.
Isah T. Rethinking Ginkgo Biloba L.: medicinal uses and conservation. Pharmacogn Rev. 2015;9(18):140-148.
Leistner E, Drewke C. Ginkgo biloba and Ginkgotoxin. J Nat Prod. 2010;73(1):86-92.
Lima ARB, Torresb RA, Jacobina UP, Pinheiro MA, Adam ML. Genomic damage in Mugil curema (Actinopterygii: Mugilidae) reveals the effects of intense urbanization on estuaries in northeastern Brazil. Mar Pollut Bull. 2019;138:63-69.
Maeda J, Kijima A, Inoue K, Ishii Y, Ichimura R, Takasu S, et al. In Vivo Genotoxicity of Ginkgo Biloba extract in gpt delta mice and constitutive androstane receptor knockout mice. Toxicol Sci. 2014;140(2):298-306.
Mei N, Guo X, Ren Z, Kobayashi D, Wada K, Guo L. Review of Ginkgo biloba -induced toxicity, from experimental studies to human case reports. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017;35(1):1-28.
MICROMEDEX® versão 2.0. Available at: Accessed on 08/18/2023.
» www.micromedexsolutions.com
Nadin SB, Vargas-Roig LM, Ciocca DR. A Silver Staining Method for Single-cell Gel Assay. J Histochem Cytochem. 2001;49(9):1183-1186.
National Toxicology Program. NTP. Technical Report on Ginkgo Biloba Extract, CAS No. 90045-36-6. NTP TR 578.; 2003.
National Toxicology Program. NTP. Technical Report on Toxicology and Carcinogenesis Studies of Ginkgo biloba Extract, CAS No. 90045-36-6. NTP TR 578.; 2013.
Organization for Economic Cooperation and Development. OECD. Guide 423 Acute Oral Toxicity - Acute Toxic Class Method, 2001.
Organization for Economic Cooperation and Development. OECD. Guide 407 Repeated Dose 28-day Oral Toxicity Study in Rodents, 2008.
Organization for Economic Cooperation and Development. OECD. Guide 489 In Vivo Mammalian Comet Assay, 2016.
Pitarque M, Creus A, Marcos R, Hughes JA, Anderson D. Examination of various biomarkers measuring genotoxic endpoints from Barcelona airport personnel. Mutat Res. 1999;440(2):195-204.
Russo P, Frustaci A, Del Bufalo A, Fini M, Cesario A. Multitarget drugs of plants origin acting on Alzheimer’s disease. Curr Med Chem. 2013;20(13):1686-1693.
Schmid W. The micronucleus test. Mutat Res. 1975;31(1):9-15.
Sehner C, Schwind M, Tuschl G, Barle EL. What to consider for a good quality PDE document? Pharm Dev Technol. 2019;24(7):803-811.
Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet. 1998;352(9121):36.
van Beek TA, Montoro P. Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J Chromatogr A. 2009;1216(11):2002-2032.
Wang CZ, Yuan JJ, Li WJ, Zhang HY, Ye JZ. In Vivo and In Vitro Toxicity Evaluation of Polyprenols Extracted from Ginkgo biloba L. Leaves. Molecules. 2015;20(12):22257-22271.
Wiesner L, Prause M, Barle EL. Topical otic drugs in a multi-purpose manufacturing facility: a guide on determination and application of permitted daily exposure (PDE). Pharm Dev Technol. 2018;23(3):261-264.
Yang G, Wang Y, Sun J, Zhang K, Liu J. Ginkgo biloba for mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Curr Top Med Chem. 2016;16(5):520-528.
Yang X, Zheng T, Hong H, Cai N, Zhou X, Sun C, et al. Neuroprotective effects of Ginkgo biloba extract and Ginkgolide B against oxygen-glucose deprivation/reoxygenation and glucose injury in a new in vitro multicellular network model. Front Med. 2018;12(3):307-318.
Zhu X, Li Z, Li C, Zhang J, Zou Z, Wang J. Ginkgo Biloba extract and aspirin synergistically attenuate activated platelet-induced ROS production and LOX-1 expression in human coronary artery endothelial cells. Phytomedicine. 2013;20(2):114-119.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
